Tag: commercial

TORONTO, 25 juill. 2025 (GLOBE NEWSWIRE) -- Investissements Purpose Inc. (« Investissements Purpose ») a annoncé aujourd’hui sa décision de dissoudre le Fonds de croissance des actions StoneCastle et le Fonds de croissance du revenu StoneCastle (chacun, un « Fonds StoneCastle » et, ensemble, les « Fonds StoneCastle ») à la fermeture des bureaux le 29 septembre 2025 ou vers cette date (la « date de dissolution des Fonds StoneCastle »). Dès maintenant, chaque Fonds StoneCastle est fermé aux nouvelles souscriptions. Investissements Purpose a également annoncé sa décision de dissoudre le Fonds de base PK à compter de la fermeture des bureaux aujourd’hui. Le Fonds de base PK n’a actuellement aucun porteur de parts et est fermé aux nouveaux achats.

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

WASHINGTON, July 25, 2025 (GLOBE NEWSWIRE) -- EB5 Capital is pleased to announce the first individual I-526E petition approval for an investor in its Charlotte Eagle Lake (JF42) project. An I-526E approval is a significant step in the EB-5 immigration process as it qualifies the investor and their eligible family members for conditional permanent residency in the United States. The approved petition was filed in January 2025 and was pending for approximately six months.

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025